Clinical features of MPN/MPN-blast phase cases (unmatched and matched)
| . | Unmatched MPN . | Unmatched MPN-blast phase . | Matched MPN . | Matched MPN-blast phase . |
|---|---|---|---|---|
| All cases, no. (%) | 77 (56) | 60 (44) | 11 (50) | 11 (50) |
| MPN diagnosis no. (%) | ||||
| PV samples | 21 (27) | 17 (28) | 2 (18) | 2 (18) |
| ET samples | 31 (40) | 18 (30) | 1 (09) | 1 (09) |
| PMF samples | 25 (33) | 25 (42) | 8 (73) | 8 (73) |
| Sex, M:F | ||||
| PV samples | 1:2 | 1:1 | 1:1 | 1:1 |
| ET samples | 1:2 | 1:1 | 0:1 | 0:1 |
| PMF samples | 2:1 | 2:1 | 2:1 | 2:1 |
| Mean age at diagnosis, y, ± SD* | ||||
| PV | 57 ± 5 | 68 ± 5 | — | — |
| ET | 59 ± 6 | 69 ± 7 | — | — |
| PMF | 57 ± 6 | 65 ± 9 | 59 ± 9 | 65 ± 7 |
| Mean blast count in bone marrow, ± SD, no. (%)* | ||||
| PV samples | < 5% | 70 ± 20 | — | — |
| ET samples | < 5% | 66 ± 23 | — | — |
| PMF samples | < 5% | 70 ± 21 | < 5% | 66 ± 24 |
| JAK2V617F (+) no. (%) | ||||
| PV samples | 21/21 (100) | 14/17 (82)‡ | 2/2 (100) | 1/2 (50) |
| ET samples | 18/31 (58) | 6/18 (33) | 0/1 (0) | 0/1 (0) |
| PMF samples | 16/25 (64) | 12/25 (48) | 5/8 (62.5) | 4/8 (50) |
| c-MPL mutation positive, no. (%) | ||||
| PV samples | 1/21 (5)† | 0/17 (0) | 0/2 (0) | 0/2 (0) |
| ET samples | 0/31 (0) | 1/18 (6) | 0/1 (0) | 0/1 (0) |
| PMF samples | 3/25 (12) | 2/25 (8) | 1/8 (12.5) | 1/8 (12.5) |
| . | Unmatched MPN . | Unmatched MPN-blast phase . | Matched MPN . | Matched MPN-blast phase . |
|---|---|---|---|---|
| All cases, no. (%) | 77 (56) | 60 (44) | 11 (50) | 11 (50) |
| MPN diagnosis no. (%) | ||||
| PV samples | 21 (27) | 17 (28) | 2 (18) | 2 (18) |
| ET samples | 31 (40) | 18 (30) | 1 (09) | 1 (09) |
| PMF samples | 25 (33) | 25 (42) | 8 (73) | 8 (73) |
| Sex, M:F | ||||
| PV samples | 1:2 | 1:1 | 1:1 | 1:1 |
| ET samples | 1:2 | 1:1 | 0:1 | 0:1 |
| PMF samples | 2:1 | 2:1 | 2:1 | 2:1 |
| Mean age at diagnosis, y, ± SD* | ||||
| PV | 57 ± 5 | 68 ± 5 | — | — |
| ET | 59 ± 6 | 69 ± 7 | — | — |
| PMF | 57 ± 6 | 65 ± 9 | 59 ± 9 | 65 ± 7 |
| Mean blast count in bone marrow, ± SD, no. (%)* | ||||
| PV samples | < 5% | 70 ± 20 | — | — |
| ET samples | < 5% | 66 ± 23 | — | — |
| PMF samples | < 5% | 70 ± 21 | < 5% | 66 ± 24 |
| JAK2V617F (+) no. (%) | ||||
| PV samples | 21/21 (100) | 14/17 (82)‡ | 2/2 (100) | 1/2 (50) |
| ET samples | 18/31 (58) | 6/18 (33) | 0/1 (0) | 0/1 (0) |
| PMF samples | 16/25 (64) | 12/25 (48) | 5/8 (62.5) | 4/8 (50) |
| c-MPL mutation positive, no. (%) | ||||
| PV samples | 1/21 (5)† | 0/17 (0) | 0/2 (0) | 0/2 (0) |
| ET samples | 0/31 (0) | 1/18 (6) | 0/1 (0) | 0/1 (0) |
| PMF samples | 3/25 (12) | 2/25 (8) | 1/8 (12.5) | 1/8 (12.5) |
MPN indicates myeloproliferative neoplasm; PV, polycythemia vera; ET, essential thrombocytosis; M, male; F, female; and PMF, primary myelofibrosis.
Data are available for 27 unmatched MPN (10 PV, 10 ET, and 7 PMF) and 54 unmatched MPN-blast phase (15 PV, 18 ET, and 21 PMF) cases, and 8 matched MPN (PMF) cases.
This c-MPL mutation in a PV patient has already been validated and reported by Kawamata et al.8
Significantly fewer cases with JAK2V617F in blast phase vs chronic phase (P=.045).